Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Shares of Insulet Co. (NASDAQ:PODD – Get Free Report) have received an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the company, MarketBeat ...